Journal of Clinical Pathology 2007;60:709-714
ORIGINAL ARTICLE
Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis
1 Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
2 Department of Pathology, Buffalo General Hospital, Buffalo, New York, USA
3 Institute of Pathology, Basel University Hospital, Basel, Switzerland
4 Department of Pathology, University Medical Center Hamburg, Eppendorf, Hamburg, Germany
5 Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland
Correspondence to:
Correspondence to:
Professor P Mhawech-Fauceglia
Department of Pathology, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA; pmhawech1{at}yahoo.com
Background: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin’s lymphoma (B-NHL), Hodgkin’s lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored.
Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
Results: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
Conclusion: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
Abbreviations: HL, Hodgkin’s lymphoma; IHC, immunohistochemistry; MCC, Merkel cell carcinoma; NHL, non-Hodgkin’s lymphoma; PAX, pair box; RT, reverse transcriptase; SCC, small cell carcinoma; UC, urothelial carcinoma
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
jcp.2006.039917v1
60/6/709 most recent - Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Immunology (including allergy)
-
Breast cancer
-
Endocrine cancer
-
Gynecological cancer
-
Lung cancer (oncology)
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
